Neurocrine Biosciences Stock Price and Value Analysis

Should you buy Neurocrine Biosciences stock? (NasdaqGS:NBIX). Let's see how it does in our automated value investing analysis system.

NBIX Free Cash Flow Trend

Free Cash Flow trendline for NBIX
Free Cash Flow trendline for Neurocrine Biosciences

Hmm, we can't give any reliable projection for Neurocrine Biosciences's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company is not making money.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the NBIX Numbers

NBIX Price
(Neurocrine Biosciences stock price per share)
[?] PE Ratio versus Sector 245% higher than other Healthcare stocks
[?] PE Ratio versus Industry 21% higher than other Biotechnology stocks
[?] Cash Yield -0.31%
[?] Free Cash Flow Jitter 141%

Is Neurocrine Biosciences Stock on Sale?

Based on our analysis, we believe that you should not buy Neurocrine Biosciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NBIX Stock?

Does Neurocrine Biosciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.